Search results
Results from the WOW.Com Content Network
On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for ...
Exact Sciences (NASDAQ: EXAS) Q3 2024 Earnings Call Nov 05, 2024, 5:00 p.m. ET. ... This news release and today's presentation are available on our website at exactsciences.com. During today's ...
The company said it plans to complete submission of its marketing application for the new test to the U.S. Food and Drug Administration (FDA) by the end of this year. The company reported $1.43 ...
Exact Sciences Corp. is an American molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer ; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer .
Genomic Health, Inc. was founded in 2000 by Randy Scott, who had previously founded and been CEO at Incyte. [4] He formed the company after a close friend was diagnosed with cancer and had the idea for treatment based on the specific genome of their tumor.
Biomatrica, Inc. is a United States-based biotechnology company, and subsidiary of Exact Sciences Corporation, that develops chemicals for ambient temperature preservation of biological materials for the purpose of expanding the availability and accuracy of medical diagnostics and research.
Date. Firm. Action. From. To. Feb 2022. Wells Fargo. Maintains. Equal-Weight. Feb 2022. Citigroup. Maintains. Neutral. Feb 2022. Raymond James. Maintains. Outperform
Exact Sciences (EXAS) delivered earnings and revenue surprises of 12.15% and 5.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?